Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BGI Changes Direction at Complete Genomics; Cuts Staff

publication date: Nov 27, 2015
BGI, the Shenzhen-based genomics sequencing company, has re-purposed its US subsidiary, Complete Genomics of Mountain View, California, and ordered significant staff reductions. When BGI bought CG in 2013, CG was a service provider, offering its Long Fragment Read technology for whole genome sequencing, which CG claimed provided more accurate readings. As recently as a month ago, CG's mission was to support commercial launch of its $12 million Revolocity genomic sequencer, a large, powerful machine with 200-300 potential global customers. Now, CG will support BGI's BGISEQ-500, a smaller desktop sequencer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital